Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer

被引：0
|
作者：
Sarah E. Burnette
Emily Poehlein
Hui-Jie Lee
Jeremy Force
Kelly Westbrook
Heather N. Moore
机构：
[1] Atrium Health Wake Forest Baptist,Department of Pharmacy
[2] Duke University,Department of Biostatistics and Bioinformatics
[3] Duke University Cancer Institute,Department of Breast Oncology
[4] Duke University Medical Center,Department of Pharmacy
来源：
Breast Cancer Research and Treatment | 2023年 / 197卷
关键词：
Alpelisib; Metastatic breast cancer; Hormone-receptor positive; PIK3CA; Hyperglycemia; Rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：369 / 376
页数：7
相关论文
共 50 条
  • [41] PIK3CA Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Cescon, David W.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) : 1318 - +
  • [42] Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) plus fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
    Andre, F.
    Rugo, H. S.
    Juric, D.
    Rubovsky, G.
    Yamashita, T.
    Stemmer, S. M.
    Lu, Y- S.
    Miller, M. K.
    Lorenzo, I.
    Hu, H.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S498 - S499
  • [43] EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) plus /dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL).
    Gradishar, William John
    Farooki, Azeez
    Giridhar, Karthik
    Moore, Heather
    Johnston, Abigail
    Miller, Michelle Kristine
    Wang, Craig
    Reising, Albert
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
    Li, Junjie
    Wang, Zhonghua
    Shao, Zhimin
    CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
  • [45] Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Brufsky, Adam M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 137 - 147
  • [46] Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 526 - 534
  • [47] Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
    Raphael, Ari
    Salmon-Divon, Mali
    Epstein, Jessica
    Zahavi, Tamar
    Sonnenblick, Amir
    Shachar, Shlomit S.
    GENES, 2022, 13 (10)
  • [48] Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021
    Mezni, Essia
    Sabatier, Renaud
    Goncalves, Anthony
    Vicier, Cecile
    BULLETIN DU CANCER, 2022, 109 (02) : 216 - 225
  • [49] AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER plus /human epidermal growth factor receptor 2-negative (HER2-)PIK3CA-mutated advanced breast cancer
    Campone, Mario
    Bardia, Aditya
    Kabos, Peter
    Chandarlapaty, Sarat
    Neven, Patrick
    Boni, Valentina
    Lord, Simon
    Cartot-Cotton, Sylvaine
    Celanovic, Marina
    Gosselin, Alice
    Pelekanou, Vasiliki
    Linden, Hannah M.
    CANCER RESEARCH, 2022, 82 (04)
  • [50] PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Rasti, Aryana R.
    Guimaraes-Young, Amy
    Datko, Farrah
    Borges, Virginia F.
    Aisner, Dara L.
    Shagisultanova, Elena
    JCO PRECISION ONCOLOGY, 2022, 6
12345